Ranolazine: focusing on angina pectoris.

Peter A McCullough

Journal: Drugs of today (Barcelona, Spain : 1998) 2006;42(3):177-83

PMID: 16628259

Full Text on Clarivate Analytics View on PubMed

Abstract

Chronic stable angina is common and is a difficult-to-manage problem when patients begin to fail conventional therapy especially when maximal revascularization has been provided. The most promising agent in development is ranolazine, a late sodium channel inhibitor and partial fatty oxidation inhibitor which has unique and desirable anti-ischemic and electrophysiologic properties. This agent is likely to become standard therapy for chronic stable angina and may play a future role in the management of acute coronary syndromes.

Address: Department of Medicine, Divisions of Cardiology, Nutrition and Preventive Medicine, William Beaumont Hospital, Royal Oak, Michigan 48073, USA. [email protected]

DOI: 10.1358/dot.2006.42.3.953590

Link outs

Free resources

Medical:

https://medlineplus.gov/angina.html

Subscription / membership required

Full Text Sources:

https://doi.org/10.1358/dot.2006.42.3.953590

MeSH Terms: Acetanilides, Angina Pectoris, Enzyme Inhibitors, Humans, Piperazines, Randomized Controlled Trials as Topic, Ranolazine